# Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

> **NCT07428993** · PHASE2 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Pediatric Osteosarcoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna
- **PROCEDURE:** Apheresis
- **PROCEDURE:** SJCARB7H3_41BBL infusion

## Key facts

- **NCT ID:** NCT07428993
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2034-12
- **Final completion:** 2035-12
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428993, "Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07428993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*